A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Status:
Not yet recruiting

Trial end date:
2024-01-15

Target enrollment:

Participant gender:

This is a clinical research study to learn if pembrolizumab in combination with lenvatinib can help to control pancreatic ductal adenocarcinoma.

Early Phase 1

M.D. Anderson Cancer Center

STRATEGIC ALLIANCE: Merck

Lenvatinib
Pembrolizumab